FDA grant fast track status to CAR T cell therapy for kidney cancer
The Food and Drug Administration (FDA) in America has granted [...]
Perioperative nivolumab in intermediate/high risk kidney cancer patients
The standard of care for patients with intermediate/high risk kidney [...]
Patient perspectives on immunotherapy dosing schedules
Immunotherapy (in particular immune checkpoint inhibitors) has transformed the treatment [...]
ASCO 2024: Treatment-free survival with cabozantinib plus nivolumab
At the American Society of Clinical Oncology Annual Meeting (ASCO) last [...]
Summary of kidney cancer highlights from ASCO 2024
This year’s American Society of Clinical Oncology (ASCO) Annual Meeting [...]
Stereotactic radiotherapy plus immunotherapy for brain metastases
Stereotactic radiosurgery (SRS) is a procedure that uses special equipment [...]
Video interview: The new cancer vaccine
We are excited to be able to show you this [...]
Kidney cancer mutation found in 70% of Japanese patients
An international study involving 11 countries, including Japan, the United [...]
Treatment options in first-line metastatic kidney cancer
Over the past 10 years or so, the use of [...]
Comparison of cabozantinib with axitinib as second-line treatment for metastatic kidney cancer
To date, there have not been any studies that have [...]
